In case p53 is mutated, a combination of small molecules reactivating mutant p53, such as PRIMA or MIRA-1 [56], together with calcitriol (or an analog to avoid hypercalcemia by high vitamin D3 doses) may lead to the inhibition of cancer progression. This evidence concerns the gene TP53 and hypercalcemia disease.